TY - JOUR
T1 - Sulfobutylether-β-cyclodextrin
T2 - A functional biopolymer for drug delivery applications
AU - Pardeshi, Chandrakantsing V.
AU - Kothawade, Rucha V.
AU - Markad, Ashwini R.
AU - Pardeshi, Sagar R.
AU - Kulkarni, Abhijeet D.
AU - Chaudhari, Prashant J.
AU - Longhi, Marcela R.
AU - Dhas, Namdev
AU - Naik, Jitendra B.
AU - Surana, Sanjay J.
AU - García, Mónica C.
N1 - Funding Information:
The authors are thankful to CyDex Pharmaceuticals Inc. (Kansas, United States) for providing a for free sample of Captisol®, for research purpose. Longhi MR and García MC are members of the Argentinean National Council for Scientific and Technical Research (CONICET)’s scientific career. The authors wish to acknowledge the assistance of the CONICET and the National University of Cordoba (UNC, Argentina), both of which provided facilities for this work.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Sulfobutylether β-cyclodextrin (SBE-β-CD) is a polyanionic cyclic oligosaccharide that contains glucopyranose units forming a torus ring-like structure. SBE-β-CD is gifted with many favorable properties viz. relatively high solubility (>50 folds compared to β-CD), improved stability, and biocompatibility that praised SBE-β-CD as a smart polymer for drug delivery applications. Commercially, SBE-β-CD is popular by its brand name Captisol®. The present review discusses the structure, properties, and preparation methods of SBE-β-CD-based inclusion complexes (ICs). Furthermore, we discuss here the preparation and applications of SBE-β-CD ICs-based nanoparticulate drug delivery systems, which combines the merits of both, ICs (enhanced solubility) and nanoparticles (NPs, targeted therapy). Patents on and FDA-approved Captisol®-enabled products are tabulated in the benefit of readers. The toxicological aspects and current clinical status of SBE-β-CD or SBE-β-CD-based products are briefly explained in the present review. In our opinion, the present review would be a pathfinder to allow dissemination of information on SBE-β-CD.
AB - Sulfobutylether β-cyclodextrin (SBE-β-CD) is a polyanionic cyclic oligosaccharide that contains glucopyranose units forming a torus ring-like structure. SBE-β-CD is gifted with many favorable properties viz. relatively high solubility (>50 folds compared to β-CD), improved stability, and biocompatibility that praised SBE-β-CD as a smart polymer for drug delivery applications. Commercially, SBE-β-CD is popular by its brand name Captisol®. The present review discusses the structure, properties, and preparation methods of SBE-β-CD-based inclusion complexes (ICs). Furthermore, we discuss here the preparation and applications of SBE-β-CD ICs-based nanoparticulate drug delivery systems, which combines the merits of both, ICs (enhanced solubility) and nanoparticles (NPs, targeted therapy). Patents on and FDA-approved Captisol®-enabled products are tabulated in the benefit of readers. The toxicological aspects and current clinical status of SBE-β-CD or SBE-β-CD-based products are briefly explained in the present review. In our opinion, the present review would be a pathfinder to allow dissemination of information on SBE-β-CD.
UR - https://www.scopus.com/pages/publications/85142337549
UR - https://www.scopus.com/pages/publications/85142337549#tab=citedBy
U2 - 10.1016/j.carbpol.2022.120347
DO - 10.1016/j.carbpol.2022.120347
M3 - Review article
AN - SCOPUS:85142337549
SN - 0144-8617
VL - 301
JO - Carbohydrate Polymers
JF - Carbohydrate Polymers
M1 - 120347
ER -